Key Takeaways:
- Intellia Therapeutics (NTLA, Financial) has been upgraded to "Outperform" by Wolfe Research, pushing the stock up by over 10%.
- Analysts have set ambitious price targets, indicating potential significant upside for investors.
- Current metrics suggest room for substantial growth from Intellia's present stock price.
Intellia Therapeutics (NTLA) experienced a significant surge in its stock price, climbing by over 10%, following an upgrade from Wolfe Research to an "Outperform" rating. This upgrade comes with a new price target of $21, indicating a potential upside of nearly 190% from the stock's recent closing price of $7.23. Despite facing recent hurdles, Intellia Therapeutics exhibits promising growth potential that has caught the attention of analysts.
Wall Street Analysts' Forecast
According to data collected from 23 analysts, the one-year price targets for Intellia Therapeutics Inc (NTLA, Financial) set an average at $43.78. The highest estimate reaches $106.00, while the lowest is $8.00. The average target price suggests a remarkable potential upside of 447.97% from the current stock price of $7.99. Investors seeking more comprehensive estimate data can explore the Intellia Therapeutics Inc (NTLA) Forecast page.
The consensus from 28 brokerage firms places Intellia Therapeutics Inc (NTLA, Financial) with an average brokerage recommendation of 2.1, reflecting an "Outperform" status. The recommendation scale ranges from 1 (Strong Buy) to 5 (Sell), positioning Intellia as a favorable investment opportunity.
GuruFocus Value Analysis
As per GuruFocus estimates, the projected GF Value for Intellia Therapeutics Inc (NTLA, Financial) over the next year is $28.51. This estimation signals an upside potential of 256.82% from the current price of $7.99. The GF Value is calculated based on historical trading multiples, past business growth, and future performance estimates. For further insights, visit the Intellia Therapeutics Inc (NTLA) Summary page.
Investors are keeping a keen eye on Intellia Therapeutics, as its recent stock upgrade and promising metrics suggest significant opportunities for growth.
